AL

If I lost what matters most to me… What would I give to have it back? Everything. So what do I already have? Everything. After my own health battles, this reminder hits different. Family. Breath. Another shot at tomorrow. Gratitude isn’t soft — it’s rocket fuel. What’s one thing you’d give everything to keep? Serious answers, funny ones, or total chaos — all welcome. Reply below 👇 Tag someone who needs this today.

Biotech is rebounding in 2026, but $IBRX is on another level. ANKTIVA delivered $44.2M Q1 2026 revenue (+168% YoY, +15% QoQ) — building on $113M full-year 2025 (+700% YoY). businesswire.com/news/home/2026… Unique IL-15 superagonist activating NK + T cells. Approved/authorized in ~34 countries, incl. first-ever lung cancer nod in Saudi. immunitybio.com/saudi-fda-gran… +293% YTD vs XBI ~+12%. Commercial traction + platform upside in a sea of pre-revenue bets. High risk/reward. DYOR. #Biotech #Immunotherapy

🚨 $IBRX shorts are bleeding hard. 135.54 million shares shorted (~$1.03 billion position at current ~$7.60 price). At recent ~7.5-8% borrow fee = roughly $6.5–7 MILLION per month in interest alone. Every day they hold, the pain compounds. High short interest + rising borrow costs = classic squeeze setup. Who’s paying that bill? Short interest 👉 marketbeat.com/stocks/NASDAQ/… Borrow rates 👉 fintel.io/ss/us/ibrx CTB updates 👉 chartexchange.com/symbol/nasdaq-…

🚨 FDA warning letter vaporized ~$2B of $IBRX market cap in one day over a @seanspicer podcast & TV ad (NEVER aired) hyping Anktiva. Dr. Patrick Soon-Shiong (@DrPatrick) was simply repeating what the NCI/government said years ago in journals: IL-15 (Anktiva’s core) ranked #1 immunotherapy with greatest potential to cure cancer (2007 NCI report). Lawsuits hitting the COMPANY? Should hit the FDA for this fishy overreach crushing innovation. Company yanked it all & fixed compliance. @RobertKennedyJr @DrMakaryFDA FDA Letter 👉 fda.gov/inspections-co… NCI 2007 report 👉 sitc.sitcancer.org/news/nci_manus… Company response 👉 ir.immunitybio.com/news-releases/…

The power of NK cells. Decoding sepsis with immunotherapy. Clinical trials open and more to come. Addressing lymphopenia in sepsis. ALC matters. clinicaltrials.gov/study/NCT07492… sciencedirect.com/science/articl…

$IBRX @getgoing4life ask me to post this which I agree! Dear @DrMakaryFDA ImmunityBio submitted its TV ad to the FDA for review and approval before airing it — exactly as the regulatory process requires. The FDA rejected it, so the ad was never broadcast. That part is standard procedure. What’s not standard is what happened next. After the market opened (when material news is almost never released), the FDA publicly attacked the company for following its own procedures. The result: IBRX’s stock was crushed ~25% in a single day. This timing and tone raise serious questions. It appears the FDA may have acted in coordination with — or under influence from — big pharma interests and short sellers. Shortly afterward, plaintiffs’ lawyers piled on with lawsuits citing the FDA’s seemingly unlawful actions. The FDA desperately needs immediate reform. It should be overhauled and staffed with experienced industry professionals elected by their peers, not populated by the revolving door that currently funnels talent straight into big pharma. Too many lives are being lost while regulators allegedly protect profits instead of patients. This isn’t oversight — it looks like obstruction. @DrPatrick @LoriMills4CA42

This could be a MAJOR shift in cancer treatment. Activating your body’s own “special forces” (NK & T cells) to fight cancer… and the FDA sends a warning? @DrPatrick explains Watch now @ @SeanMSpicer" target="_blank" rel="nofollow noopener">youtube.com/@SeanMSpicer

The $IBRX setup is legit: Fintel data matches exactly (134M shorted, 34.94% float, 10.79 days to cover, 59% dark pool shorts). ANKTIVA's Q1 record $44M revenue + Macau approval + AACR data next week are real tailwinds amid BCG shortages. Shorts are squeezed on prior rallies. Estimated high in next 2 weeks: $10.20 (momentum + borrow fees ~9-16% could accelerate covering if volume spikes; recent range 6.8-7.8 supports 30-40% run on catalyst). High volatility—watch for pullbacks on any news.

🚨 $IBRX SHORT SQUEEZE SETUP IS ABSOLUTELY NUCLEAR RIGHT NOW 🔥 Check the fresh data straight from @fintel_io (screenshot attached): • 134,199,301 shares shorted • 34.94% of the float — one of the highest in the entire market • 10.79 days to cover — that’s not “high,” that’s a multi-day traffic jam waiting to happen • 59.03% off-exchange short volume ratio (dark pool shorting at extreme levels) The stock is already +6% today to ~$7.40, and this is no random pump. Real catalysts are hitting hard: • Anktiva (their bladder cancer immunotherapy) just posted record commercial revenue and is expanding globally (Macau approval + more coming) • Persistent BCG shortage is a structural tailwind — hospitals literally need alternatives and Anktiva is stepping up • Founder @DrPatrick just dropped fresh data linking COVID immune damage to cancer recurrence — presentation coming at AACR next week • Pivotal BCG-naïve trial fully enrolled → supplemental BLA expected later in 2026 Insiders and institutions own a huge chunk → effective float is even tighter than the headline number. This is the classic squeeze formula: Massive short interest + real product momentum + tightening supply of shares = shorts getting forced to cover at accelerating prices. We’ve already seen shorts eat hundreds of millions in paper losses on earlier 2026 rallies. The fuse is lit. $IBRX isn’t some meme — it’s a commercial-stage biotech with a differentiated drug that shorts have been fighting for years… and they’re still buried at these levels. Data source: @fintel_io → fintel.io/ss/us/ibrx Company: @ImmunityBio Founder updates: @DrPatrick This one has real teeth. Watch the volume and borrow rates — when they spike, it’s game over for the shorts. (Not financial advice — always DYOR. But the setup doesn’t get much cleaner than this.) Who’s loading? 👀 $IBRX #ShortSqueeze

$IBRX just dropped strong prelim Q1 2026 results today: ANKTIVA net product revenue ~$44.2M (+168% YoY, +15% QoQ). Cash & securities: $380.9M. Full-year 2025 revenue hit $113M (+700% YoY). Pipeline advancing (BCG-naïve trial enrolled, sBLAs on track). At ~$7 levels, looks undervalued. My base case: $10–12 (40–70% upside). Analyst consensus target ~$14.40. Risks remain (burn, execution, FDA overhang). Not advice—DYOR! PR: ir.immunitybio.com/news-releases/… Analyst targets: marketbeat.com/stocks/NASDAQ/…

@spaventa7 Just along for the ride with the market right now. Once this Iran stuff settles the market should bounce back. Seems like a pretty good buy opportunity.

@ALulko Now selling off… I just don’t understand the price action here

$IBRX looking primed for a breakout! 🟢 Price action holding steady near $7.30–$7.50 with strong volume and bullish setup after the recent pullback — healthy base forming for the next leg up. Most recent news: Today (4/6/26), ImmunityBio addressed FDA correspondence on advertising and reaffirmed full commitment to compliance. Just weeks ago (3/31/26), they strengthened the balance sheet with $100M financing — including $75M non-dilutive — to fuel global ANKTIVA® expansion and the broader immunotherapy pipeline. Plus: NCCN guidelines update, Macau approval, sBLA on track, and massive revenue momentum. Bullish catalysts stacking up! Sources: ir.immunitybio.com/company/press-… businesswire.com/news/home/2026… #IBRX #ImmunityBio #Biotech NFA — DYOR 🚀

@NoobTrader1314 I'd take a look at XBI and SPY. Seems like we're just following the market. Hold and add. seems like we only have good news from here.

@ALulko why we droppin today?

Treating patients dying of sepsis only with antibiotics and cardiac supportive care while ignoring the collapse of the immune system is like a horse with blinders and with limited peripheral vision. The year of the fire horse is here. Scientific research on the dynamic state of immune dysfunction and lymphopenia in patients dying of sepsis coming soon. Stay tuned. Sepsis is the most expensive condition managed in U.S. hospitals. Hospital costs for sepsis soared from $31.2 billion in 2016 to $52.1 billion in 2021. In 2021, one in six patients with sepsis died in the hospital; among sepsis hospital encounters involving septic shock, one in three stays resulted in death. hcup-us.ahrq.gov/reports/Sepsis…

$IBRX @ImmunityBio Dunkirk!

My dad, Allen Lulko, was taken by Non-Hodgkin’s Lymphoma at just 42. He fought hard, stayed positive and selfless — always putting his wife Shelly and kids (Danielle, Michael, and me) first, even asking only for more time with us, not a cure. I grew up without my father because cancer won that battle in 2004. Today we have real hope. @ImmunityBio $IBRX — let’s make sure no more kids grow up missing their dad. Cure cancer. Honor the fighters. ❤️ lifestorynet.com/obituaries/all…”

Imagine we rid the world of cancer tomorrow: Gov saves $200B+ yearly on treatment. Millions live longer → trillions more in taxes from extended productive lives. One report: $185 TRILLION economic windfall. foxnews.com/politics/cure-… @realDonaldTrump @elonmusk @DrPatrick @ImmunityBio $IBRX Time to win the war on cancer! #CureCancer”

@elonmusk Elon, if there’s anyone in this world that could help influence curing cancer, it would be you. You could be our savior! Please link up with Dr. Pats (@DrPatrick) and his company @ImmunityBio ($IBRX) — their immunotherapy breakthroughs are game-changing. Together you could save millions of lives. Let’s make it happen! 🚀🧬 #CureCancer #IBRX

Capital in place.Approvals in 34 countries. Indication expansion globally in motion. Pipeline of combination trials cooking. Immunotherapy 2.0. Never give up.

Insider signal is strong: Founder-affiliated entity converting debt to equity shows conviction. Markets reacting positively (stock up pre-market/intraday). This shifts $IBRX from “prove it” to “scale it” mode. Non-dilutive growth capital + high-margin commercial momentum = bullish setup for the next 12-18 months. Full PR: ir.immunitybio.com/news-releases/… What do you think — loading up or watching? $IBRX

Why today's PR matters. • ANKTIVA already delivered ~700% YoY revenue growth in 2025 with ~99% gross margins • Approvals/authorization now in ~34 countries (US, UK, EU bloc, Saudi Arabia — including first lung cancer nod — Macau & more) • Removes funding overhang → runway extended for commercial scale-up, manufacturing, and pipeline (BCG-naïve NMIBC BLA targeted 2026, lung cancer expansions, etc.) Management can now focus on execution instead of financing.